Best Biotech Stocks to Buy Now (2024)Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.
Industry: Biotechnology
| Ticker | Company | Country | Market Cap | Shares | Institutional % | Insider % | Net Insider (L12M) | Net Insider (L3M) |
|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | United States | $2.55B | 104,112,088 | 30.65% | 69.35% | Net Buying | Net Buying |
| INCY | INCYTE CORP | United States | $12.07B | 224,540,751 | 79.30% | 20.70% | Net Selling | Net Buying |
| AMLX | AMYLYX PHARMACEUTICALS INC | United States | $137.60M | 67,782,139 | 52.42% | 47.58% | Net Buying | Net Selling |
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | United States | $1.79B | 56,791,861 | 61.03% | 38.97% | Net Selling | Net Selling |
| PBYI | PUMA BIOTECHNOLOGY INC | United States | $234.44M | 48,238,850 | 55.16% | 44.40% | Net Selling | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | United States | $15.65B | 189,879,803 | 97.46% | 1.62% | Net Selling | Net Selling |
| EXEL | EXELIXIS INC | United States | $6.38B | 291,292,704 | 88.76% | 4.24% | Net Selling | Net Buying |
| VYGR | VOYAGER THERAPEUTICS INC | United States | $478.39M | 54,300,627 | 47.14% | 52.86% | Net Selling | Net Selling |
| HALO | HALOZYME THERAPEUTICS INC | United States | $5.06B | 126,824,800 | 78.21% | 21.79% | Net Selling | Net Selling |
| GMAB | GENMAB A | Denmark | $19.65B | 66,122,964 | 70.47% | 0.00% | ||
| UTHR | UNITED THERAPEUTICS CORP | United States | $11.64B | 44,355,694 | 87.59% | 12.41% | Net Selling | Net Selling |
| TGTX | TG THERAPEUTICS INC | United States | $2.50B | 154,420,772 | 53.78% | 46.22% | Net Selling | Net Selling |
| ROIV | ROIVANT SCIENCES LTD | Bermuda | $9.18B | 805,846,006 | 40.14% | 59.86% | Net Selling | Net Selling |
| RPRX | ROYALTY PHARMA PLC | United States | $16.97B | 597,434,791 | 51.02% | 16.51% | Net Selling | Net Buying |
| MEIP | MEI PHARMA INC | United States | $20.39M | 6,662,857 | 17.91% | 82.09% | Net Buying | |
| BNTX | BIONTECH SE | Germany | $22.04B | 237,725,735 | 17.05% | 0.00% | ||
| MDXG | MIMEDX GROUP INC | United States | $1.09B | 147,603,955 | 42.42% | 57.58% | Net Buying | Net Selling |
| REGN | REGENERON PHARMACEUTICALS INC | United States | $105.45B | 110,185,503 | 69.34% | 30.66% | Net Selling | Net Buying |
| VNDA | VANDA PHARMACEUTICALS INC | United States | $280.78M | 57,537,499 | 56.23% | 43.77% | Net Selling | Net Selling |
| SRPT | SAREPTA THERAPEUTICS INC | United States | $12.63B | 94,523,766 | 73.88% | 26.12% | Net Buying | Net Selling |
| SPRO | SPERO THERAPEUTICS INC | United States | $87.81M | 53,869,139 | 25.60% | 64.13% | Net Selling | |
| AVRO | AVROBIO INC | United States | $54.73M | 44,860,515 | 46.76% | 53.24% | Net Selling | |
| BNOX | BIONOMICS LIMITED | Australia | $11.09M | 1,924,808,444 | 0.07% | 0.00% | ||
| VRTX | VERTEX PHARMACEUTICALS INC | United States | $103.60B | 258,307,816 | 90.91% | 1.48% | Net Selling | Net Selling |
| KRYS | KRYSTAL BIOTECH INC | United States | $4.56B | 28,292,616 | 75.55% | 24.45% | Net Selling | Net Selling |
| CPRX | CATALYST PHARMACEUTICALS INC | United States | $1.73B | 117,863,258 | 71.64% | 16.33% | Net Buying | Net Selling |
| CRSP | CRISPR THERAPEUTICS AG | Switzerland | $4.49B | 80,275,950 | 62.44% | 37.56% | Net Buying | Net Buying |
| TFFP | TFF PHARMACEUTICALS INC | United States | $5.11M | 2,519,220 | 3.17% | 96.83% | Net Buying | |
| KNSA | KINIKSA PHARMACEUTICALS LTD | Bermuda | $1.42B | 70,940,145 | 48.25% | 9.83% | Net Selling | Net Selling |
| OCUP | OCUPHIRE PHARMA INC | United States | $49.38M | 24,813,370 | 1.23% | 98.77% | Net Buying | Net Buying |
| PLX | PROTALIX BIOTHERAPEUTICS INC | Israel | $83.28M | 73,052,124 | 6.75% | 93.25% | Net Buying | |
| SEER | SEER INC | United States | $145.09M | 64,773,180 | 54.70% | 45.30% | Net Buying | Net Selling |
| ADAG | ADAGENE INC | China | $106.32M | 55,145,839 | 12.92% | 0.00% | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | Ireland | $6.93B | 63,039,618 | 26.94% | 73.06% | Net Selling | Net Selling |
| MIRM | MIRUM PHARMACEUTICALS INC | United States | $1.21B | 47,003,329 | 48.94% | 51.06% | Net Buying | Net Selling |
| IMMP | IMMUTEP LTD | Australia | $335.25M | 1,188,834,559 | 0.17% | 0.00% | ||
| VYNE | VYNE THERAPEUTICS INC | United States | $36.94M | 14,098,888 | 23.19% | 76.81% | Net Buying | Net Selling |
| DBVT | DBV TECHNOLOGIES SA | France | $128.64M | 96,431,770 | 39.10% | 15.37% | Net Buying | Net Buying |
| PRTA | PROTHENA CORP PUBLIC LTD CO | Ireland | $1.23B | 53,720,455 | 53.06% | 46.94% | Net Buying | |
| IDYA | IDEAYA BIOSCIENCES INC | United States | $3.14B | 74,560,273 | 88.70% | 10.03% | Net Selling | Net Selling |
| CLGN | COLLPLANT BIOTECHNOLOGIES LTD | Israel | $68.14M | 11,452,672 | 12.49% | 0.00% | ||
| RNA | AVIDITY BIOSCIENCES INC | United States | $2.11B | 79,719,473 | 82.47% | 17.53% | Net Selling | Net Selling |
| VTGN | VISTAGEN THERAPEUTICS INC | United States | $121.61M | 27,025,209 | 38.92% | 61.08% | Net Buying | |
| LPCN | LIPOCINE INC | United States | $24.88M | 5,315,830 | 5.77% | 94.23% | Net Buying | |
| ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | United States | $733.98M | 26,915,243 | 87.10% | 12.90% | Net Selling | Net Selling |
| ORMP | ORAMED PHARMACEUTICALS INC | United States | $95.22M | 40,519,160 | 12.73% | 46.50% | ||
| INM | INMED PHARMACEUTICALS INC | Canada | $1.47M | 6,056,970 | 13.28% | 11.17% | Net Buying | Net Buying |
| ALGS | ALIGOS THERAPEUTICS INC | United States | $61.29M | 75,668,521 | 54.25% | 45.75% | Net Buying | |
| KZR | KEZAR LIFE SCIENCES INC | United States | $62.39M | 72,801,359 | 67.83% | 21.82% | Net Buying | |
| GNFT | GENFIT SA | France | $182.40M | 49,834,983 | 1.27% | 0.00% | ||
| MDWD | MEDIWOUND LTD | Israel | $171.99M | 9,221,764 | 27.28% | 0.00% | ||
| ZYME | ZYMEWORKS INC | Canada | $650.48M | 70,704,890 | 61.32% | 38.68% | Net Buying | |
| ANIX | ANIXA BIOSCIENCES INC | United States | $93.79M | 31,899,800 | 13.83% | 84.71% | Net Buying | Net Buying |
| AXSM | AXSOME THERAPEUTICS INC | United States | $3.54B | 47,374,375 | 71.00% | 29.00% | Net Selling | Net Buying |
| LEGN | LEGEND BIOTECH CORP | United States | $8.26B | 363,822,069 | 23.61% | 0.00% | ||
| NVO | NOVO NORDISK A S | Denmark | $554.96B | 4,510,000,000 | 6.84% | 0.00% | ||
| AGIO | AGIOS PHARMACEUTICALS INC | United States | $1.96B | 56,772,966 | 75.09% | 24.91% | Net Selling | Net Selling |
| PTGX | PROTAGONIST THERAPEUTICS INC | United States | $1.52B | 58,274,998 | 79.94% | 20.06% | Net Selling | Net Selling |
| FULC | FULCRUM THERAPEUTICS INC | United States | $480.00M | 61,935,171 | 64.02% | 35.98% | Net Buying | Net Buying |
| XCUR | EXICURE INC | United States | $4.33M | 8,648,307 | 0.89% | 99.11% | Net Selling | Net Selling |
| MRUS | MERUS NV | Netherlands | $2.80B | 57,878,284 | 87.00% | 13.00% | Net Selling | |
| FUSN | FUSION PHARMACEUTICALS INC | Canada | $1.82B | 84,692,585 | 71.20% | 28.80% | ||
| ACIU | AC IMMUNE SA | Switzerland | $237.08M | 99,197,829 | 29.88% | 0.00% | ||
| FATE | FATE THERAPEUTICS INC | United States | $402.90M | 99,237,508 | 61.86% | 38.14% | Net Selling | Net Selling |
| ARGX | ARGENX SE | Belgium | $22.98B | 59,194,488 | 55.29% | 0.00% | ||
| XBIO | XENETIC BIOSCIENCES INC | United States | $6.58M | 1,540,684 | 0.42% | 99.58% | ||
| SLGL | SOL-GEL TECHNOLOGIES LTD | Israel | $23.68M | 27,857,620 | 28.59% | 0.00% | ||
| CLNN | CLENE INC | United States | $55.87M | 128,430,098 | 9.06% | 52.69% | Net Buying | Net Selling |
| JANX | JANUX THERAPEUTICS INC | United States | $3.35B | 51,660,060 | 54.14% | 45.86% | Net Buying | |
| IGMS | IGM BIOSCIENCES INC | United States | $591.98M | 58,786,588 | 37.27% | 54.63% | Net Buying | Net Buying |
| VERV | VERVE THERAPEUTICS INC | United States | $536.00M | 83,619,279 | 62.25% | 37.75% | Net Buying | Net Selling |
| TRAW | TRAWS PHARMA INC | United States | $13.38M | 21,040,645 | 5.95% | 94.05% | Net Selling | Net Selling |
| MRKR | MARKER THERAPEUTICS INC | United States | $37.57M | 8,902,897 | 1.30% | 98.70% | ||
| ZVRA | ZEVRA THERAPEUTICS INC | United States | $208.88M | 43,426,186 | 29.20% | 27.84% | Net Buying | |
| ALT | ALTIMMUNE INC | United States | $517.54M | 70,895,286 | 34.70% | 65.30% | Net Selling | |
| ITOS | ITEOS THERAPEUTICS INC | United States | $417.93M | 35,843,131 | 62.37% | 37.63% | Net Selling | |
| CDIO | CARDIO DIAGNOSTICS HOLDINGS INC | United States | $16.56M | 21,591,119 | 7.67% | 34.34% | Net Buying | Net Buying |
| PLRX | PLIANT THERAPEUTICS INC | United States | $842.14M | 60,239,176 | 70.74% | 29.26% | Net Selling | |
| BGNE | BEIGENE LTD | Cayman Islands | $16.98B | 1,359,513,224 | 3.31% | 34.70% | Net Selling | Net Selling |
| SPRB | SPRUCE BIOSCIENCES INC | United States | $30.61M | 41,149,160 | 63.59% | 36.41% | Net Selling | Net Selling |
| TECH | BIO-TECHNE CORP | United States | $12.15B | 157,191,685 | 97.66% | 2.34% | Net Buying | Net Selling |
| RVMD | REVOLUTION MEDICINES INC | United States | $6.62B | 164,690,408 | 89.46% | 10.54% | Net Selling | Net Selling |
| CALT | CALLIDITAS THERAPEUTICS AB | Sweden | $595.80M | 59,580,087 | 1.42% | 0.00% | ||
| BRNS | BARINTHUS BIOTHERAPEUTICS PLC | United Kingdom | $84.85M | 38,921,212 | 24.97% | 54.37% | Net Buying | |
| SPRY | ARS PHARMACEUTICALS INC | United States | $940.89M | 96,501,554 | 43.67% | 56.33% | Net Buying | Net Buying |
| EYPT | EYEPOINT PHARMACEUTICALS INC | United States | $983.66M | 49,830,792 | 20.11% | 79.89% | Net Selling | Net Buying |
| RYTM | RHYTHM PHARMACEUTICALS INC | United States | $2.63B | 60,140,495 | 87.96% | 12.04% | Net Selling | Net Selling |
| APRE | APREA THERAPEUTICS INC | United States | $29.05M | 5,430,215 | 1.54% | 98.46% | Net Buying | Net Buying |
| IFRX | INFLARX NV | Germany | $81.26M | 58,883,272 | 29.00% | 0.00% | ||
| SAGE | SAGE THERAPEUTICS INC | United States | $838.94M | 60,182,031 | 71.61% | 28.39% | Net Selling | |
| LXRX | LEXICON PHARMACEUTICALS INC | United States | $428.45M | 246,236,753 | 21.34% | 78.66% | Net Buying | Net Buying |
| QSI | QUANTUM-SI INC | United States | $260.86M | 141,769,917 | 36.43% | 63.57% | Net Buying | Net Buying |
| IMCR | IMMUNOCORE HOLDINGS PLC | United Kingdom | $3.00B | 49,820,613 | 75.26% | 0.07% | Net Buying | Net Buying |
| KRRO | KORRO BIO INC | United States | $467.20M | 8,021,946 | 18.90% | 81.10% | Net Buying | Net Buying |
| ZLAB | ZAI LAB LTD | China | $1.61B | 992,087,430 | 4.15% | 1.96% | Net Buying | Net Buying |
| MREO | MEREO BIOPHARMA GROUP PLC | United Kingdom | $457.24M | 701,287,029 | 11.20% | 4.59% | ||
| VCYT | VERACYTE INC | United States | $1.53B | 75,067,823 | 64.44% | 35.56% | Net Selling | Net Selling |
| VRDN | VIRIDIAN THERAPEUTICS INC | United States | $966.62M | 62,767,570 | 67.46% | 32.54% | Net Buying | |
| IMTX | IMMATICS NV | Germany | $911.76M | 84,657,789 | 58.58% | 0.00% | ||
| OCS | OCULIS HOLDING AG | Switzerland | $469.12M | 36,649,705 | 10.87% | 0.00% |
Biotech Stocks FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.